Alpha Cognition Inc. reports developments as a commercial-stage biopharmaceutical company focused on neurodegenerative diseases, with ZUNVEYL oral tablets as its commercial product for Alzheimer’s disease. Company news commonly covers financial results, business updates, long-term care commercialization, and the commercial and clinical positioning of its lead assets.
Updates also address ALPHA-1062 development, including programs related to Alzheimer’s dementia and cognitive impairment with mild traumatic brain injury, as well as patent activity for traumatic brain injury applications. Other recurring announcements include investor conference participation, board composition, executive and employee equity awards, and Nasdaq-related governance disclosures.
Alpha Cognition (ACOG) announced publication of a U.S. patent application covering benzgalantamine for treating persistent symptoms following mild traumatic brain injury. Application 20260325541-A1, titled “Benzgalantamine for Treating Persistent Post-Concussion Symptoms,” includes pending treatment-method claims covering cognitive impairment and multiple administration routes.
The application includes preclinical animal data evaluating sensorimotor and cognitive recovery, neuronal preservation, new neuron formation, lesion volume, and pathological phosphorylated tau. Alpha Cognition views the publication as supporting potential development beyond Alzheimer’s disease; the claims remain pending.
Alpha Cognition (ACOG) reported third-quarter 2026 ZUNVEYL net product revenue of approximately $7.8 million, driven by increased sales volume. Revenue rose approximately 30% sequentially and more than 230% year over year. Bottles dispensed reached 10,896, while cumulative prescribers reached 2,410, exceeding the original full-year goal a quarter early.
Operating loss was approximately $6.4 million, versus $7.1 million in Q2 2026 and $3.4 million a year earlier. Net loss was approximately $7.6 million. Cash totaled approximately $37.8 million, with no debt. Full-year R&D and administrative and selling expense guidance remains $50 million to $54 million.
In CONVERGE, 79.1% of residents new to the drug class reached a therapeutic dose on ZUNVEYL within 180 days, versus 37.3% on generic alternatives. The retrospective, unadjusted analysis does not establish causality. The company continues to target operating profitability in 2027.
Alpha Cognition (Nasdaq: ACOG) appointed Caren Deardorf to its Board of Directors, effective November 9, 2026, adding pharmaceutical commercial leadership experience. Deardorf currently serves as Chief Business & Strategy Officer at Neutrolis and previously held commercial leadership roles at Editas Medicine, Magenta Therapeutics and Ohana Biosciences.
Her career includes 20 years at Biogen, where she led the launch of SPINRAZA and ultimately served as Vice President, Global Product Development & Commercialization Lead for its spinal muscular atrophy portfolio. She also served on Crinetics’ board from March 2022 through its acquisition by Vertex Pharmaceuticals. Alpha Cognition expects her experience to support the commercial launch of ZUNVEYL, its approved Alzheimer’s treatment, and continued development of its sublingual program.
Alpha Cognition (Nasdaq: ACOG) will participate in investor events on November 17 and December 10, 2026, with its CEO and COO. Michael McFadden, CEO, and Lauren D’Angelo, COO, will participate in the Craig-Hallum Alpha Select Conference, featuring one-on-one meetings, and the Stonegate CEO Series, featuring a fireside chat at 12pm EST on December 10.
Alpha Cognition (Nasdaq: ACOG) will report third-quarter 2026 financial results and provide a business update on November 11, 2026. The announcement is scheduled for 4:30 p.m. Eastern Time, after market close. Management will host a conference call following the release to review financial and operating results. Results and accompanying materials will be available in the website’s News section, with a call replay available three hours afterward in the Events section.
Alpha Cognition (ACOG) announced publication of a U.S. patent application covering its proprietary manufacturing process for benzgalantamine, the active ingredient in ZUNVEYL.
The USPTO published application No. 19/090,242, titled “Process for Preparing Benzgalantamine and Salts Thereof,” on October 1, 2026, as US 2026/0297103 A1. Alpha Cognition said the technology is intended to support consistent commercial-scale production of high-purity benzgalantamine. The application describes methods for controlling product characteristics relevant to manufacturing reliability and stability.
Alpha Cognition (ACOG) will present new ZUNVEYL clinical and real-world data at the ASCP Annual Meeting and NEI Fall Congress.
ASCP takes place October 29-November 1, 2026, followed by NEI on November 5-8, 2026. The scheduled posters examine cognition, daily functioning, neuropsychiatric symptoms, sleep, gastrointestinal tolerability and medication use in residents with Alzheimer’s disease, primarily in long-term care. ASCP presentations also cover treatment transitions to benzgalantamine, ZUNVEYL’s drug name, and a subgroup previously treated with donepezil. NEI presentations focus on cognitive and functional outcomes and symptom and medication-use analyses from the BEACON Study. An ASCP literature review addresses acetylcholinesterase inhibitors, a class of Alzheimer’s treatments, and CMS psychotropic quality measures.
Alpha Cognition (ACOG) granted stock options covering 6,000 common shares to a new non-executive employee on October 1, 2026.
The Compensation Committee approved the award under the 2026 Inducement Grant Plan as an employment inducement in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price is $8.70 per share, equal to the closing share price on the grant date. The options vest over three years: one-third on the first anniversary of the grant and the remaining two-thirds in equal quarterly installments over the following two years. Vesting requires the employee’s continued service through each applicable vesting date.
Alpha Cognition (ACOG) announced initial CONVERGE results comparing ZUNVEYL dosing and other medication use with generic therapies in long-term care residents.
The ongoing retrospective analysis assessed 180-day patterns. Among residents new to acetylcholinesterase inhibitors, drugs that inhibit an enzyme that breaks down acetylcholine, and starting at the initial dose, 79.1% reached therapeutic dosing with ZUNVEYL versus 37.3% with pooled generics. Across all starting doses, rates were 79.2% versus 53.7% for new users and 80.7% versus 54.0% for residents previously treated with another such drug. Other medication-class burden decreased across all eight evaluated classes with ZUNVEYL and increased with generics.
The analyses were unadjusted for potential confounders and do not establish causality. Alpha Cognition expects dataset updates in December 2026 and March 2027 to expand future analyses.
Alpha Cognition (ACOG) granted an inducement award of nonstatutory stock options to purchase 25,000 common shares to a new non-executive employee on September 8, 2026, under its 2026 Inducement Grant Plan in line with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $9.52 per share, equal to the closing price of the company’s stock on the grant date. Vesting occurs over three years: one-third on the first anniversary of the grant, and the remaining two-thirds in equal quarterly installments over the following two years, subject to continued service. The options are governed by the 2026 Inducement Grant Plan and an applicable stock option agreement. Alpha Cognition is a commercial-stage biopharmaceutical company focused on neurodegenerative diseases and markets the Alzheimer’s treatment ZUNVEYL.